The association between the diversity of the oral microbiome and PFS
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, AT. This podcast outlines a study that aimed to determine the impact of the oral microbiome in patients uniformly treated with ixazomib + thalidomide + dexamethasone combination therapy for the treatment of relapsed/refractory MM.
Oral microbiome characteristics are highly heterogeneous between patients, and a higher microbiome diversity has been associated with favorable prognosis in patients with…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.